Detalles de la búsqueda
1.
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.
Nephrol Dial Transplant
; 38(8): 1890-1897, 2023 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36565721
2.
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
Respir Res
; 22(1): 184, 2021 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158028
3.
Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
Respir Res
; 22(1): 171, 2021 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34098955
4.
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
N Engl J Med
; 376(20): 1921-1932, 2017 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28514601
5.
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
J Allergy Clin Immunol
; 143(6): 2170-2177, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578883
6.
Association of depressive symptoms with health status and markers of uncontrolled severe asthma.
Allergy Asthma Proc
; 40(4): 230-239, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31262378
7.
Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
Pulm Pharmacol Ther
; 41: 19-24, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27599598
8.
Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma.
Clin Exp Allergy
; 50(7): 869-872, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515118
9.
Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
Allergy
; 75(8): 2085-2088, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32147844
10.
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
J Allergy Clin Immunol
; 131(2): 461-7.e1-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23040887
11.
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
Ann Rheum Dis
; 70(12): 2119-25, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21859685
12.
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.
J Asthma Allergy
; 14: 675-683, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34163180
13.
Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
J Allergy Clin Immunol Pract
; 9(9): 3506-3509.e3, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34111572
14.
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
PLoS One
; 11(6): e0157961, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27336685
15.
A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Adv Ther
; 32(2): 157-71, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25700806
16.
Update on immunogenicity in severe asthma: Experience with mepolizumab.
J Allergy Clin Immunol Pract
; 7(7): 2469-2475.e1, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30954640
Resultados
1 -
16
de 16
1
Próxima >
>>